During ASMS 2024, which will take place June 2–6, 2024 in Anaheim, California, many scientists are set to present research on the latest advances in mass spectrometry. Recently, LCGC International sat down with Elizabeth Neumann of the University of California, Davis to discuss her presentation, "Multi-Site Reproducibility Trial of MALDI-IHC Multiplexed Targeted Protein Imaging using a 33-Organ Tissue Microarray."
Elizabeth Neumann is an Assistant Professor in the Department of Chemistry at the University of California, Davis. She has been a NIH Postdoctoral Fellow at Vanderbilt University, a NSF Doctoral Fellow at University of Illinois at Urbana-Champaign, and she has earned a BS in Chemistry from Baylor University (1). Her lab joined the UC Davis Chemistry Department in the summer of 2022 and focuses on understanding the molecular and cellular architecture behind neurological diseases. The research is highly interdisciplinary and involves developing analytical tools and multimodal imaging methods for understanding complex biological phenomena.
In this interview, Neumann answers the following questions:
To see more about what ASMS 2024 will have in store, see our interviews with Peter Horvatovich of the University of Groningen and Nick Riley of the University of Washington.
(1) Elizabeth Neumann. The Regents of the University of California, Davis campus 2022. https://chemistry.ucdavis.edu/people/elizabeth-neumann (accessed 2024-5-28)
Advancing Bladder Cancer Research with Mass Spectrometry: A FeMS Interview with Marta Relvas-Santos
November 12th 2024LCGC International interviewed FeMS Empowerment Award winner Marta Relvas-Santos on her use of mass spectrometry to identify potential biomarkers and therapies for bladder cancer. She also shared insights on her work with FeMS and advice for fellow scientists.
Pharmaceutical excipients, such as polyethylene glycol-based polymers, must be tested for the presence of ethylene oxide (EtO) and 1,4-dioxane as part of a safety assessment, according to USP Chapter <228>.